Get SEC filing alerts via email and in your feed for CURIS INC
CRIS
CURIS INC
About CURIS INC
Curis, Inc. is a biotechnology company focused on developing targeted cancer therapies, primarily through small molecule inhibitors like emavusertib targeting IRAK4. It operates in immuno-oncology and precision oncology, collaborating with partners such as Aurigene and Genentech. The company advances drug candidates through preclinical and clinical trials, seeking regulatory approvals and licensing its technologies to generate revenue from royalties and milestone payments.
This description was generated via AI from an annual report.
Updated 8 months ago.